Sort
11,323 grants matching “glioblastoma”
Therapeutic disruption of Connexin43-mediated microtubule regulation to target glioblastoma cancer stem cells
$224,999Samy Lamouille · Acomhal Research, Inc. · R41 · FY2017 · CA
Novel Immunotherapy for Brain Cancer
$224,988Andrew C Hiatt · Mapp Biopharmaceutical, Inc. · R43 · FY2014 · CA
Dual Targeted Nanoparticle therapy for Glioblastoma Multiforme
$224,980Randal Singh Goomer · Avrygen Corporation · U43 · FY2014 · CA
TRAIL Upregulation by TIC10 Analogs
$224,960Gary L Olson · Provid Pharmaceuticals, Inc · R43 · FY2014 · CA
The Role of Non-Coding RNA Editing in MET Signaling in NSCLC
$224,918Mario Acunzo · Virginia Commonwealth University · R21 · FY2023 · CA
MECHANISMS OF CELLULAR RADIOSENSITIVITY
$224,906Johns Hopkins University · P01 · FY2000 · CA
Oncolytic Immunotherapy of Malignant Glioma
$224,888Matthias Gromeier · Duke University · P50 · FY2014 · CA
Genetic Modulation of Cognitive Function and outcomes in Glioblastoma Patients
$224,839Melissa L Bondy · University Of Tx Md Anderson Can Ctr · P50 · FY2008 · CA
INBRE RESEARCH CORE
$224,826Ulhas P Naik · University Of Delaware · P20 · FY2008 · RR
Development of self-delivering RNAi to evaluate PTEN as a therapeutic target to p
$224,789Lisa J McKerracher · Bioaxone Biosciences, Inc. · R43 · FY2014 · NS
Administrative and Clinical Services Core
$224,780Susan M Chang · University Of California, San Francisco · P01 · FY2017 · CA
Clinical efficacy of the antitumor agent ONC201 in GBM
$224,700Wolfgang Oster · Oncoceutics, Inc. · R44 · FY2017 · CA
Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance
$224,633Jing Zhou · Isoplexis, Inc. · R44 · FY2018 · CA
Measles Virotherapy for Glioblastoma Multiforme
$224,632Evanthia Galanis · Mayo Clinic Rochester · R21 · FY2007 · CA
Rheb GTPase as chemotherapeutic target for brain tumors
$224,630Lawrence A Quilliam · Indiana University Indianapolis · R01 · FY2009 · CA
Rheb GTPase as chemotherapeutic target for brain tumors
$224,630Lawrence A Quilliam · Indiana University Indianapolis · R01 · FY2008 · CA
Rheb GTPase as chemotherapeutic target for brain tumors
$224,630Lawrence A Quilliam · Indiana Univ-Purdue Univ At Indianapolis · R01 · FY2007 · CA
Targeted Pharmacological Chaperones for Neurological Diseases
$224,593John J Naleway · Marker Gene Technologies · R43 · FY2015 · NS
The molecular mechanism of isocitrate dehydrogenase (lDH) mutations in cancer
$224,577Christal Dyane Sohl · San Diego State University · R00 · FY2016 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2015 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2009 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2012 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2010 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2016 · CA
Novel microtubule-targeting agents for the treatment of glioblastoma multiform
$224,564Nephi Stella · University Of Washington · R21 · FY2019 · NS